Genetics Sample Clauses

Genetics. In terms of genetic features, populations speaking Chibchan languages show a rather homogeneous picture and have peculiarities that set them apart from other indigenous groups in the Americas (e.g., Xxxxxxxxx 1990; Xxxxx et al. 2013). It has repeatedly been observed, for instance, that the diversity of mitochondrial DNA (mtDNA) is relatively low among populations speaking Chibchan languages (Xxxxxx et al. 2007). Four main mtDNA haplogroups occur in the Americas (A, B, C, and D), indicating four founding mother lineages of Amerind people (Xxxxxx & Xxxxxx 2004; Xxxxxxxxxxx et al. 1995), and a clear pattern emerges for peoples speaking Chibchan languages, namely a high proportion of haplogroup A, and a near absence of haplogroup D (Torroni et al. 1994; Xxxxxxx et al. 1995; Xxxxxx et al. 2002; Xxxxxx et al. 1994; Xxxxxx et al. 2007; Xxxxxx 2008). A possible interpretation of this relatively uniform picture is genetic drift, due to a small founding population (cf. Xxxx 1942) with little subsequent gene flow, that is, little subsequent admixture of women with different mtDNA. The investigation of autosomes, which include information from both parents, likewise produces a homogeneous picture: A slightly lower level of heterozygosity among Chibchan- speaking groups (compared with neighboring populations) was observed by Xxxx et al. (2007: 2060), who investigated genome-wide patterns of variation among Amerindian peoples, namely 678 autosomal microsatellite markers. These reduced levels of heterozygosity among Chibchan-speaking groups may likewise reflect genetic drift, that is, a rather small Proto-Chibchan founding population, which may have spread relatively recently or not over the Intermediate Area. 4 The only gold artifact from the Intermediate Area that arguably reached eastern South America is a double-headed eagle or vulture made of guanín, which was dredged from the bottom of the mid-Mazaruni river in Guyana (Xxxxxxxxx 1990), and which is “pure Colombian in style” (Xxxx 1997: 47). Genetic data suggest a relatively close link between Chibchan-speaking groups and peoples from eastern South America. In terms of external relations as reflected in autosomal markers, Xxxx et al. (2007) find strong support (97%) for clustering together the Cabécar, Guaymí (Ngäbe), Ika, Kogi, with the geographically adjacent Wayuu (Maipuran), Zenú (unknown linguistic affiliation), Emberá and Waunana (both Chocoan). Additionally, the authors propose “a reasonably well-supported cl...
AutoNDA by SimpleDocs
Genetics. Any treatment, device, drug, or supply to alter the body’s genes, genetic make-up, or the expression of the body’s genes except for the correction of congenital birth defects.
Genetics. Seals are primarily rehabilitated for animal welfare reasons. No negative effects of rehabilitation on the populations have yet been documented. It is, however, sometimes argued that release of rehabilitated animals may eventually have negative consequences for the population where there are individuals with genetic weaknesses among the admitted seals. Orphanage (both seals species) and parasitic pneumonia (common seals only) are the main causes of seals being admitted to rehabilitation (Chapter 1). For orphans, disturbance and extreme weather conditions are considered to be the most probable causes of separations between mothers and their pups. These two factors are expected to affect the seals in a random manner. A number of marine mammal studies postulate a relationship between disease and heterozygosity, which is the level of genetic variation within an individual animal selected at random from the population (Xxxxxxx- Xxxxxxxxxx et al. 2003; Xxxxxxxxx et al. 2004; Xxxxx et al. 2008). Disease can also be related to a specific locus rather than overall genetic variability (Xxxxx et al. 2005; Xxxxxxx- Xxxxxxxxxx et al. 2009).
Genetics. RA is a complex disease and is often heterogeneous in its clinical presentation. This heterogeneity can continue throughout the course of disease with variable disease progression, severity and response to treatment. This variability between individuals is likely secondary to genetic factors. The role of HLA DRB1 genes has been known for many years. The first clue that T cells may be an important driver of inflammation in RA came with the discovery of the link between RA and HLA-DR4/DR1 [Winchester 1981]. The only known function of DR molecules is to present antigen to T cells. Several different HLA DRB1 alleles have been shown to be associated with RA and some alleles have much stronger associations than others; HLA DRB1*0404 is a much stronger susceptibility factor than HLA DRB1*0401. [Xxxxxx et al. 1992] In contrast some HLA DRB1 alleles may actually be protective. Recent thinking suggests that the association between HLA DRB1 and RA is related to severity of disease rather than risk of development of disease. [Xxxx et al. 1994] Twin studies have shown that RA has a heritability of approximately 60%. [XxxXxxxxx et al. 2000]
Genetics. There is considerable evidence that genetic susceptibility plays a role in the pro- gression from substance use to dependence and ultimately addiction. Like for most diseases, the genetic contribution to addiction is highly complex, as heredity reflects both the variance attributable to genetic factors themselves and the variance result- ing from interactions between genes and environment 132. Thus, genetic factors not only determine individual differences in drug pharmacokinetics and vulnerability to the reinforcing properties of drugs, but also susceptibility to the effects of life events thereupon 710. Twin studies have indicated that addictions are among the most heritable of psy- chiatric disorders 254. Although most research has focused on alcohol and tobacco abuse, which have much higher prevalences that illicit drug use, several studies have indicated that there is a substantial genetic component in vulnerability to the reinforcing properties of cocaine 348,670, which is more pronounced for cocaine abuse than use 348. Interestingly, it has been proposed that the genetic component in drug addiction is not substance-specific but rather extends to all classes of abused drugs 349. In addition, there may be genes that are specific to a certain type of drug and its neurobiological and pharmacological profile. Studies in humans have identified several genes that are associated with cocaine dependence, of which the D2 receptor gene has gained most attention. There is a strong association between cocaine dependence and certain alleles of the D2 receptor gene (A1 and B1) 475 and the A1 allele has also been associated with the occurrence of severe alcoholism 121, nicotine and opioid dependence, polysub- stance abuse and obesity (for a review see: 473,476). Conflicting data have, however, also been reported 231. Carriers of the A1 allele have lower numbers of D2 receptors in the striatal complex and several additional metabolic and neurophysiological differences within dopamine rich brain regions (reviewed in: 474). Interestingly, this allele has also been associated with the occurrence of post-traumatic stress disorder (PTSD) 123, which is intriguing in view of the high co-morbidity between PTSD and drug abuse (see section 5.5). This finding suggests that the D2 receptor gene might engage in gene-environment interactions, which has been supported by studies showing that cigarette craving 198 and cognitive function 41 were differentially af- fected by stress i...
Genetics. It might be considered as the ultimate proof of causality when subjects who are exposed to high CRP their whole life due to genetic predisposition have increased risk of CVD. No environmental factors that determine risk are expected to contribute in this analysis. Very recently, it has become firmly established that a genetic component exists for basal levels of CRP. Baseline levels of CRP show a clear heritability of 40% 55 and 39% 56 in family studies. In twin studies, XxxXxxxxx and colleagues57 observed 26% heritability in middle-aged twins; xx Xxxx et al (unpublished data, 2004) observed heritability of 20% in elderly twins. Xxxxx et al58 reported the involvement of genetics to CRP, not only with respect to baseline CRP levels, but in particular to the response to stimuli. Genetic research on CRP can add to knowledge about the mechanisms of involvement of CRP in disease processes that may affect the use of CRP as a marker. Important lessons can be learned from the genetic approach and the consequences of the results. Xxxxxx et al59 reported on a GT repeat polymorphism in intron 1 of the CRP gene. Alleles that are associated with low CRP levels differ in length by exactly 10 bp, which is sufficient for one complete turn of helical double-stranded DNA. This polymorphism disrupts a consensus sequence for the hormone response element HRE-3, suggesting that this polymorphism directly affects the regulation of CRP expression. Xxx and colleagues reported no association between CRP haplotype, consisting of the exonic 1059G/C (dbSNP rs1800947) and the intronic T/A (dbSNP rs1417938) polymorphisms, and venous thromboembolism in a nested case-control sample of the Physicians Health Study60. They had reported previously that the CRP concentrations were significantly reduced among carriers of the 1059C-allele, but the polymorphism was not associated with risk of arterial thrombosis61. A more extensive haplotype analysis in 586 UK simplex systemic lupus erythematosus (SLE) families, including –286C/T/A (dbSNP rs 3091244), 188L/L (1059G/C, dbSNP rs1800947), 988C/T (dbSNP rs1130864), 1846G/A (dbSNP rs1205) and CRP(GT)n, showed that there was a strong linkage disequilibrium within the CRP gene. The rare allele of the 1846G/A polymorphism was associated with the development of SLE. The 188L/L and the 1846G/A polymorphisms made independent contributions to the basal CRP level in these subjects. For the 3’ polymorphism (dbSNP rs1205) this association may be explained by an...

Related to Genetics

  • University Any notice may be served upon the University by delivering it, in writing, to the University at the address set forth on the last page of this Agreement, by depositing it in a United States Postal Service deposit box with the postage fully prepaid and with the notice addressed to the University at the aforementioned address, or by sending a facsimile of it to the University facsimile number set forth on the last page of this Agreement.

  • Generelt A. Apple Inc. (“Apple”) giver hermed licenstager licens til at bruge Apple-softwaren, evt. tredjepartssoftware, dokumentation, , grænseflader, indhold, skrifter og evt. data, som følger med denne licens, uanset om de er præinstalleret på Apple-hardware, forefindes på disk, som ROM (Read Only Memory), på andet medie eller i anden form (under et kaldet “Apple-softwaren”) i henhold til betingelserne i denne licensaftale. Apple og/eller Apples licensgivere bevarer ejendomsretten til selve Apple-softwaren og forbeholder sig alle de rettigheder, som ikke udtrykkeligt er givet til licenstager. B. Apple vil efter eget valg evt. frigive fremtidige opgraderinger eller opdateringer til Apple-softwaren til licenstagers computer fra Apple. Evt. opgraderinger og opdateringer inkluderer ikke nødvendigvis alle de eksisterende softwarefunktioner eller nye funktioner, som Apple frigiver til nyere modeller af computere fra Apple. Licenstagers rettigheder i henhold til denne licens omfatter alle de softwareopgraderinger eller -opdateringer leveret af Apple til Apple-softwareproduktet, medmindre opgraderingerne eller opdateringerne indeholder en separat licens, i hvilket fald licenstager erklærer sig indforstået med, at betingelserne i den licens er gældende for sådanne opgraderinger eller opdateringer.

  • Cornerstone shall notify the LLC and confirm such advice in writing (i) when the filing of any post-effective amendment to the Registration Statement or supplement to the Prospectus is required, when the same is filed and, in the case of the Registration Statement and any post-effective amendment, when the same becomes effective, (ii) of any request by the Securities and Exchange Commission for any amendment of or supplement to the Registration Statement or the Prospectus or for additional information and (iii) of the entry of any stop order suspending the effectiveness of the Registration Statement or the initiation or threatening of any proceedings for that purpose, and, if such stop order shall be entered, Cornerstone shall use its best efforts promptly to obtain the lifting thereof.

  • Clinical Management for Behavioral Health Services (CMBHS) System 1. request access to CMBHS via the CMBHS Helpline at (000) 000-0000. 2. use the CMBHS time frames specified by System Agency. 3. use System Agency-specified functionality of the CMBHS in its entirety. 4. submit all bills and reports to System Agency through the CMBHS, unless otherwise instructed.

  • Manufacturing Technology Transfer Upon AbbVie’s written request with respect to a given Collaboration CAR-T Product and Licensed Product, Caribou shall effect a full transfer to AbbVie or its designee (which designee may be an Affiliate or a Third Party Provider) of all Materials and Know-How Controlled by Caribou relating to the then-current process for the Manufacture of such Collaboration CAR-T Product and any corresponding Licensed Products (each, a “Manufacturing Process”). Caribou shall provide, shall cause its Affiliates to provide, and shall use Commercially Reasonable Efforts to assist AbbVie in causing all Third Party Providers to provide, all reasonable assistance requested by AbbVie to enable AbbVie (or its Affiliate or designated Third Party Provider, as applicable) to implement each Manufacturing Process at the facilities designated by AbbVie. If requested by AbbVie, such assistance shall include facilitating the entering into of agreements with applicable Third Party suppliers relating to such Collaboration CAR-T Product and any corresponding Licensed Products. Without limitation of the foregoing, in connection with the Manufacturing Process and related transfer: (a) Caribou shall, and shall cause its Affiliates to, make available to AbbVie (or its Affiliate or designated Third Party Provider, as applicable), and shall use Commercially Reasonable Efforts to assist AbbVie in causing all Third Party Providers to make available to AbbVie, from time to time as AbbVie may request, all Materials and Manufacturing-related Know-How Controlled by Caribou relating to each Manufacturing Process, including methods, reagents and processes and testing/characterization Know-How, and all documentation constituting material support, performance advice, shop practice, standard operating procedures, specifications as to Materials to be used, and control methods, that are necessary or reasonably useful to enable AbbVie (or its Affiliate or designated Third Party manufacturer, as applicable) to use and practice such Manufacturing Process; (b) Caribou shall cause all appropriate employees and representatives of Caribou and its Affiliates, and shall use Commercially Reasonable Efforts to assist AbbVie in causing all appropriate employees and representatives of Third Party Providers, to meet with employees or representatives of AbbVie (or its Affiliate or designated Third Party Provider, as applicable) at the applicable manufacturing facility at mutually convenient times to assist with the working up and use of each Manufacturing Process and with the training of the personnel of AbbVie (or its Affiliate or designated Third Party Provider, as applicable) to the extent necessary or reasonably useful to enable AbbVie (or its Affiliate or designated Third Party Provider, as applicable) to use and practice such Manufacturing Process; (c) Without limiting the generality of this Section 4.4.2, Caribou shall cause all appropriate analytical and quality control laboratory employees and representatives of Caribou and its Affiliates, and shall use Commercially Reasonable Efforts to assist AbbVie in causing all appropriate analytical and quality control laboratory employees and representatives of Third Party Providers, to meet with employees or representatives of AbbVie (or its Affiliate or designated Third Party Provider, as applicable) at the applicable manufacturing facility and make available all necessary equipment, at mutually convenient times, to support and execute the provision of all applicable analytical methods and the validation thereof (including all applicable Know-How, Information and Materials Controlled by Caribou, and sufficient supplies of all primary and other reference standards); (d) Caribou shall, and shall cause its Affiliates to, take such steps, and shall use Commercially Reasonable Efforts to assist AbbVie in causing Third Party Providers take such steps, as are necessary or reasonably useful to assist AbbVie (or its Affiliate or designated Third Party Provider, as applicable) in obtaining any necessary licenses, permits or approvals from Regulatory Authorities with respect to the Manufacture of the applicable Collaboration CAR-T Products and corresponding Licensed Products at the applicable facilities; and (e) Caribou shall, and shall cause its Affiliates to, provide, and shall use Commercially Reasonable Efforts to assist AbbVie in causing Third Party Providers to provide, such other assistance as AbbVie (or its Affiliate or designated Third Party Provider, as applicable) may reasonably request to enable AbbVie (or its Affiliate or designated Third Party Provider, as applicable) to use and practice each Manufacturing Process and otherwise to Manufacture the applicable Collaboration CAR-T Products and corresponding Licensed Products.

  • Digital Health The HSP agrees to: (a) assist the LHIN to implement provincial Digital Health priorities for 2017-18 and thereafter in accordance with the Accountability Agreement, as may be amended or replaced from time to time; (b) comply with any technical and information management standards, including those related to data, architecture, technology, privacy and security set for health service providers by MOHLTC or the LHIN within the timeframes set by MOHLTC or the LHIN as the case may be; (c) implement and use the approved provincial Digital Health solutions identified in the LHIN Digital Health plan; (d) implement technology solutions that are compatible or interoperable with the provincial blueprint and with the LHIN Cluster Digital Health plan; and (e) include in its annual Planning Submissions, plans for achieving Digital Health priority initiatives.

  • Technology Research Analyst Job# 1810 General Characteristics

  • Xxxxx, Haldimand, Norfolk An employee shall be granted five working days bereavement leave with pay upon the death of the employee’s spouse, child, stepchild, parent, stepparent, legal guardian, grandchild or step-grandchild.

  • Behavioral Health Services Behavioral health services include the evaluation, management, and treatment for a mental health or substance use disorder condition. For the purpose of this plan, substance use disorder does not include addiction to or abuse of tobacco and/or caffeine. Mental health or substance use disorders are those that are listed in the most updated volume of either: • the Diagnostic and Statistical Manual of Mental Disorders (DSM) published by the American Psychiatric Association; or • the International Classification of Disease Manual (ICD) published by the World Health Organization. This plan provides parity in benefits for behavioral healthcare services. Please see Section 10 for additional information regarding behavioral healthcare parity. This plan covers behavioral health services if you are inpatient at a general or specialty hospital. See Inpatient Services in Section 3 for additional information. This plan covers services at behavioral health residential treatment facilities, which provide: • clinical treatment; • medication evaluation management; and • 24-hour on site availability of health professional staff, as required by licensing regulations. This plan covers intermediate care services, which are facility-based programs that are: • more intensive than traditional outpatient services; • less intensive than 24-hour inpatient hospital or residential treatment facility services; and • used as a step down from a higher level of care; or • used a step-up from standard care level of care. Intermediate care services include the following: • Partial Hospital Program (PHP) – PHPs are structured and medically supervised day, evening, or nighttime treatment programs providing individualized treatment plans. A PHP typically runs for five hours a day, five days per week. • Intensive Outpatient Program (IOP) – An IOP provides substantial clinical support for patients who are either in transition from a higher level of care or at risk for admission to a higher level of care. An IOP typically runs for three hours per day, three days per week.

  • Cardiff Capital Region has secured a deal worth £1.2 billion. Over its lifetime, local partners expect the City Deal to deliver up to 25,000 new jobs and leverage an additional £4 billion of private sector investment.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!